DUSA Pharmaceuticals, Inc. (NASDAQ: DUSA)

DUSA Pharmaceuticals, Inc. (NASDAQ: DUSA), an integrated dermatology pharmaceutical company, has its primary focus on developing and marketing its Levulan® Photodynamic Therapy (PDT) technology platform, and complementary dermatology products. Levulan PDT is approved to treat of Grade 1 or 2 actinic keratoses of the face or scalp. ClindaReach is the company’s other dermatology product. Additionally DUSA is researching other indications for Levulan PDT including oral Leukoplakia and the prevention of AKs and SCCs. For further information, visit the Company’s web site at www.dusapharma.com.